Alan Bye, BSc, PhD
Alan has more than 40 years of experience in senior positions in the pharmaceutical industry (Wellcome, Upjohn, Glaxo), lately as V-P Discovery Medicine, for the Psychiatry CEDD, Verona/Harlow at GSK. He has been involved with 40 successful compounds and having seen more than 300 compounds go first in to man and has a particular interest in the pre-clinical to clinical translation in the neuroscience/pain area.
David Trist, BSc, PhD
David Trist retired recently as V-P and Head of Strategy and Operations for the Psychiatry Centre of Excellence for Drug Discovery (Psychiatry CEDD) within GlaxoSmithKline (GSK). He worked for some years in Wellcome with Sir James Black on targets in the Central Nervous System (CNS) and Cardiovascular System, before moving to Glaxo, Verona, as Director of Pharmacology.
David has published some 187 scientific papers, book chapters and abstracts and has contributed to 30 candidate selections, 20 Phase II starts and 1 Phase III start.
Tino Rossi, PhD
Tino has more than 30 years experience in Drug Discovery and Development making key contributions to the discovery and development of more than 40 Drug Candidates, more than 20 First time in Human starts, and 10 Phase II initiations. His recent interest has been reducing attrition in Drug Discovery where his initiative increased the success rates for First Time in human approvals from 50% to 100%. Before joining Aptuit as V-P Scientific Liaison in July 2010 he was Head of Lead Optimization at the GSK Centre of Excellence Neuroscience, Verona.